Navigation Links
Isogenic cell models for cancer research exclusively licensed to Horizon Discovery
Date:12/9/2010

CLEVELAND With the goal of developing new, more effective and personalized cancer treatments, Horizon Discovery, based in Cambridge, England, has secured from Case Western Reserve University exclusive rights to a panel of new human isogenic cell models developed by the laboratory of Zhenghe John Wang, assistant professor of genetics at the university's School of Medicine.

The license is initially for 10 years and includes up-front fees and an ongoing royalty on product sales. The genetically engineered cell lines are based on a new technology invented by Wang and his associates two years ago.

Human isogenic cell models known as cell lines and sometimes referred to as "patients-in-a-test-tube" accurately mimic disease-causing mutations, enabling researchers to better understand how cancer manifests itself in patients and to identify the effect of drug therapies and various outcomes.

"These cell lines provide unique tools for drug discovery, because they are cells that best represent human cancers. Further research based on these cells may lead to development of new cancer therapies," Wang said.

The lines will be added to Horizon Discovery's rapidly expanding library of X-MANTM (gene X- Mutant And Normal) cell models, which are used to successfully predict which patient groups will respond to currently available and future drug treatments. Research involving Horizon Discovery's proprietary rAAV GENESIS gene-editing platform seeks to enhance drug development, leading to personalized cancer therapies.

Chris Torrance, Horizon Discovery's co-founder and chief scientific officer, said that the cell lines will help researchers decipher how disease-associated genes work and "will open up new routes to develop novel targeted therapies."

"In partnering with Horizon, we gain a tremendous opportunity to bring these unique cancer cell lines to the market," said Stacy Fening, licensing associate for life sciences in Case Western Reserve's Technology Transfer Office. "Commercial deployment of these cell lines allows them to be used to their full potential to advance academic and pharmaceutical research in the cancer field."

Horizon Discovery Executive Chairman Darrin M. Disley said he is delighted that the company is now able to provide a commercial outlet for the research at Case Western Reserve's School of Medicine.

Disley said the freshly licensed panel of cell lines "will enable our customers to better understand the endogenous proteins that are activated/expressed when a human cell picks up the mutations implicated in the onset and progression of human cancers."


'/>"/>

Contact: Marv Kropko
mrk107@case.edu
216-368-6890
Case Western Reserve University
Source:Eurekalert

Related biology news :

1. Metabolism models may explain why Alzheimers disease kills some neuron types first
2. Study improves accuracy of models for predicting ozone levels in urban areas
3. Scientists create 3-D models of whole mouse organs
4. Study paves way for new biofuels models, technologies
5. Species distribution models can exaggerate differences in environmental requirements
6. Biochemist researching computer models of protein structure that help high school, college students
7. Animal models that help translate regenerative therapies from bench to bedside
8. Computer models suggest vaccination or culling best to prevent foot-and-mouth disease
9. Small molecules found to protect cells in multiple models of Parkinsons disease
10. Species distribution models are of only limited value for predicting future mammal distributions
11. Caltech researchers show efficacy of gene therapy in mouse models of Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology today announced that ... SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription 3) B VHH13 ... cross the cell membrane and bind intracellular STAT3 and inhibit its function. Dysregulation ...
(Date:10/10/2017)... CA (PRWEB) , ... October ... ... a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today ... of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration ...
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology: